CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 150 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00450918
NCT00450918N/ACompleted

Longitudinal Study of Primary Ciliary Dyskinesia: Participants 5-18 Years of Age

University of North Carolina, Chapel Hill·observational·Posted Mar 22, 2007·Updated Oct 7, 2019

In Brief

An observational study for Primary Ciliary Dyskinesia. Completed, enrolled 150 participants across 5 sites in 2 countries.

Detailed Summary

Mucociliary clearance, in which mucus secretions are cleared from the breathing airways, is the primary defense mechanism for the lungs. Inhaled particles, including microbes that can cause infections, are normally entrapped in mucus on the airway surfaces and then cleared out by the coordinated action of tiny hair-like structures called cilia. Individuals with primary ciliary dyskinesia (PCD) have defective mucociliary clearance, which in turn leads to lung infections and disease. The purpose of this study is to determine how lung disease progresses over time in children and adolescents with PCD.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 22, 2007
Enrollment StartAug 1, 2006
Primary CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 13 yearsPosted 19.3 years ago